An Introduction to Haematology
The field of haematology is far-reaching, encompassing many conditions of the blood and blood-forming organs, including anaemia, bleeding and coagulation disorders, sickle cell disease, congenital immunodeficiency diseases, transfusion medicine and haematopoietic stem cell transplantation. There continue to be many obstacles to gene therapy but ultimately this approach holds promise in inherited blood disorders. In addition, novel anticoagulant therapies, multiplexed sensing platforms and the application of artificial intelligence in diagnosis and monitoring are proving valuable in clotting disorders.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
Paroxysmal nocturnal hemoglobinuria: from biology to bedside
Watch world-leading expert Prof. Régis Peffault de Latour explore the current treatment landscape in paroxysmal nocturnal hemoglobinuria, with a focus on translating this latest scientific evidence into clinical practice.
- Discuss the current treatment landscape for PNH
- Describe the unmet medical needs for PNH with respect to current treatment options
- Summarize the evolving treatment landscape and future approaches for the management of PNH
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Luspatercept for Beta-thalassemia – A New Horizon?
European Oncology & Haematology. 2020;16(1):16-7 DOI: https://doi.org/10.17925/EOH.2020.16.1.16
The chronic anaemia of beta-thalassemia major (b-thal) results from defective erythropoiesis secondary to a genetic defect in haemoglobin synthesis.1 Consequently, patients with moderate-to-severe disease rely on blood transfusions to maintain an adequate level of haemoglobin.2 Over time, this causes an iron-overloaded state, in addition to the possible blood-borne infections resulting from repeated transfusions.3 The widespread use of iron […]
The 1st Online Master class in Transplantation and Hematology (MATH) by IACH
The International Academy for Clinical Hematology (IACH) welcomes you to attend the 1st Online Master class in Transplantation and Hematology (MATH) Saturday, June 6, 2020 For more information, click here.
The 3rd Annual Meeting of the International Academy: Focus on Leukemia
The 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH): Focus on Leukemia October 1-3, 2020 Nice, France. Published Online: 24 February 2020
TPO agents beyond ITP: aplastic anemia, inherited thrombocytopenia and chemotherapy induced thrombocytopenia
Speaker Prof. James Bussel Learning objectives – Understand that thrombopoietic agents (TPO) impacts the stem cell and thus can have trilineage effects – Recognize that TPO agents are an important way to increase the platelet count in patients with inherited thrombocytopenia – Evaluate the tole of TPO agents in chemotherapy-induced thrombocytopenia: which patients and which […]
IACH 2019: Welcome
International Academy for Clinical Hematology IACH Prof. Mohamad Mohty The 2nd Annual Meeting of the IACH September 19-21, 2019 | Paris, France Published online: 27 February 2020
DEEP2 Trial – Key Findings in Paediatric Patients with Transfusion-dependent Thalassaemia
European Oncology & Haematology. 2019;15(2):89–90
Beta-thalassaemia is a hereditary blood disorder arising from impaired synthesis of beta globin chains, and can result in a range of outcomes from asymptomatic carriers to severe anaemia.1 Symptomatic thalassaemia presents in around 1 in 100,000 people worldwide, and 1 in 10,000 in Europe.1 Transfusion-dependent beta-thalassaemia (TDT) is the most severe form of thalassaemia requiring lifelong management […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!